Noriko Fukuhara
Overview
Explore the profile of Noriko Fukuhara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
985
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kobayashi T, Ishizawa K, Machida R, Sadachi R, Sasaki K, Kim H, et al.
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39997358
Maintenance therapy with monoclonal anti-CD20 antibody is the standard approach in patients with follicular lymphoma who initially treated and achieved response to immunochemotherapy. Maintenance therapy reduces the risk of lymphoma...
2.
Shimada K, Yamaguchi M, Kuwatsuka Y, Matsue K, Sato K, Kusumoto S, et al.
EClinicalMedicine
. 2025 Feb;
80:103078.
PMID: 39968389
Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and...
3.
Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, et al.
Leukemia
. 2025 Feb;
PMID: 39962328
A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the...
4.
Nato Y, Miyazaki K, Maruyama D, Takahashi H, Sunami K, Murakami S, et al.
Hematol Oncol
. 2025 Feb;
43(2):e70047.
PMID: 39937961
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse. Sandwich therapy comprising dose-adjusted (DA)-EPOCH-R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin,...
5.
6.
Ri M, Iida S, Saito K, Saito Y, Maruyama D, Asano A, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):29.
PMID: 39853402
Purpose: A comprehensive analysis of metabolites (metabolomics) has been proposed as a new strategy for analyzing liquid biopsies and has been applied to identify biomarkers predicting clinical responses or adverse...
7.
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, et al.
Br J Haematol
. 2025 Jan;
206(2):541-550.
PMID: 39778876
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy...
8.
Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H
Ann Hematol
. 2024 Dec;
104(1):841-845.
PMID: 39738826
Follicular lymphoma (FL) may undergo histological transformation (HT) into a more aggressive lymphoma. Although rituximab for B-cell non-Hodgkin lymphomas (B-NHL) has greatly improved the overall survival (OS) of patients with...
9.
Ichikawa S, Kato H, Morota N, Abe H, Kawajiri A, Inokura K, et al.
Ann Hematol
. 2024 Dec;
104(1):835-840.
PMID: 39694898
Although rearrangement of the MYC oncogene (MYC-R) is frequently observed in aggressive B-cell lymphomas, it is extremely rare in T-cell malignancies. A 64-year-old man who had been under observation for...
10.
Ichikawa S, Abe H, Morota N, Kawajiri A, Nakagawa R, Inokura K, et al.
Intern Med
. 2024 Nov;
PMID: 39566977
Nodal Epstein-Barr virus-positive T/NK-cell lymphoma (EB-nTNKL) is an extremely rare disease characterized by an aggressive clinical course and poor prognosis, for which treatment strategies have not yet been established. We...